Previous 10 | Next 10 |
Aimmune Therapeutics (NASDAQ: AIMT ) announces that the first patients in the U.S. are being treated with PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first approved treatment for peanut allergy. More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, St...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the first patients in the United States are being treated with PALFORZIA™ [Peanut ( Arachis hypogaea ) ...
New data from an open-label follow-on study, ARC004 , from the 52-week PALISADE trial showed a durable treatment effect of Aimmune Therapeutics' (NASDAQ: AIMT ) Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first peanut allergy treatment approved (late January) in t...
— Additional Data Highlight PALISADE Study Patient Baseline Characteristics and Associated Treatment Response — and Improvements in Self-Reported Quality of Life Following Long-Term Treatment with PALFORZIA — Survey Results Reinforce Immunotherapy Practice Patterns...
Aimmune Therapeutics (NASDAQ: AIMT) , a biopharmaceutical company that specializes in treatments for life-threatening food allergies, reported fourth-quarter results Thursday after the market close. Despite being down 14% at one point in Friday's trading, shares closed down only 2.5% on...
Image source: The Motley Fool. Aimmune Therapeutics Inc (NASDAQ: AIMT) Q4 2019 Earnings Call Feb 27, 2020 , 4:30 p.m. ET Operator Continue reading
Aimmune Therapeutics, Inc. (AIMT) Q4 2019 Results Earnings Conference Call February 27, 2020, 04:30 PM ET Company Participants DeDe Sheel - Vice President of Investor Relations Eric Bjerkholt - Chief Financial Officer Jayson Dallas - President and Chief Executive Officer Andrew...
Launch underway for FDA-approved PALFORZIA™, the first treatment for peanut allergy In-licensing of AIMab7195 monoclonal antibody as potential adjunctive treatment with select CODIT™ programs Pro-forma cash and investments of $443 million Webcast and confer...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will present at two upcoming investor conferences in March: Event: ...
Nine Abstracts Will Highlight Data Including on the First FDA-Approved Treatment for Peanut Allergy and Oral Immunotherapy Practice Implementation in a Real-World Setting Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments f...
News, Short Squeeze, Breakout and More Instantly...
Aimmune Therapeutics Inc. Company Name:
AIMT Stock Symbol:
NASDAQ Market:
Aimmune Therapeutics Inc. Website:
— Majority of Patients Experienced Low Rates of Adverse Events, Which Declined in Frequency and Severity with Continued Treatment — — Systemic Allergic Reactions and Epinephrine Use Were Low and Decreased Over Time — Aimmune Therapeutics, ...
-- Peanut Allergy is One of the Most Common Food Allergies in Europe -- -- Up to 1.6% of European Children Live with Potentially Life-Threatening Peanut Allergy -- Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Com...
VEVEY, Switzerland , Sept. 14, 2020 /PRNewswire/ -- Société des Produits Nestlé S.A. ("Nestlé") announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. ("Purchaser"), is commencing today a cash tender offer to purchase all of the outstanding shares of common s...